Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: VIVUS LLC Clear all

Conditions: Obesity
Interventions: VI-0521, topiramate, phentermine; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Obesity
Interventions: Metformin, VI-0521, Sitagliptan, Probenecid; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Vision
Interventions: Stendra 200 mg, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Sexual Dysfunction, Physiological
Interventions: Topical alprostadil (PGE-1); Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 21 Years to 60 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: Stanford, California • Cincinnati, Ohio

Conditions: Obesity
Interventions: Qsymia, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lakewood, Colorado

Conditions: Erectile Dysfunction
Interventions: avanafil, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Los Angeles, California • San Diego, California + 12 more

Conditions: Hepatic Impairment
Interventions: Phentermine and Topiramate; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Alzheimer's Disease
Interventions: VI-1121, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: San Francisco, California • Santa Monica, California • Sunrise, Florida + 8 more

Conditions: Torsades de Pointes
Interventions: VI-0521; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 19 Years to 50 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Sleep Apnea
Interventions: VI-0521, placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Erectile Dysfunction
Interventions: avanafil and enalapril, avanafil and amlodipine; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Pancreatic Adenocarcinoma
Interventions: Pancrelipase; Drug
Lead sponsor: Andrew Hendifar, MD; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obesity, Type 2 Diabetes
Interventions: VI-0521; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 2,487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: Birmingham, Alabama • Ridgefield, Connecticut • New York, New York + 3 more

Conditions: Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions: VI-0609, BiCNU; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Goodyear, Arizona • Duarte, California • Newnan, Georgia + 1 more

Conditions: Erectile Dysfunction
Interventions: placebo, avanafil; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 41
States / cities: Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 33 more

Conditions: Avanfil ADME, Semen Exposure, Sperm Function
Interventions: avanafil 200mg; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Type 2 Diabetes Mellitus
Interventions: VI-0521, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more

Conditions: Fibrosing Colonopathy
Interventions: ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy; Biological · Other
Lead sponsor: AbbVie; Industry
Eligibility: 0 Months to 99 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 123
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more

Conditions: Erectile Dysfunction
Interventions: Tamsulosin and avanafil, Doxazosin and avanafil; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Obesity
Interventions: topiramate, phentermine; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Pediatric Obesity, Childhood Obesity
Interventions: Placebo, VI-0521 Mid Dose, VI-0521 Top Dose; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Baton Rouge, Louisiana • Marrero, Louisiana • Cincinnati, Ohio + 1 more

Conditions: Erectile Dysfunction
Interventions: Placebo, Avanafil 100 mg, Avanafil 200 mg; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Jupiter, Florida • Raleigh, North Carolina • Wilmington, North Carolina

Conditions: Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight
Interventions: VI-0521 oral capsule, Placebo oral capsule, Lifestyle Modification; Drug · Behavioral
Lead sponsor: VIVUS LLC; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Norman, Oklahoma

Conditions: Diabetes
Interventions: VI-0521; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 19 Years to 70 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more

Search by objective public record fields.

A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

Safety Study Looking at the Effects of Stendra on Vision

Topical Alprostadil for Female Sexual Arousal Disorder

Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects

Study Evaluating the Effects of Avanafil on Semen Parameters

A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment

VI-1121 for the Treatment Alzheimer's Disease

A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers

A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults

Drug Interaction Study of Avanafil and Enalapril or Amlodipine

Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions

A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED

A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects

Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin

Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults

A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents

Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction

A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity

Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults